News

Published on 8 May 2024 on Insider Monkey via Yahoo Finance

Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Q1 2024 Earnings Call Transcript


Article preview image

Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Q1 2024 Earnings Call Transcript May 7, 2024

Ligand Pharmaceuticals Incorporated beats earnings expectations. Reported EPS is $4.75, expectations were $1.13. LGND isn't one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here).

Operator: Thank you for standing by. Our name is Benjamin and I will be your conference operator today. At this time, I would like to welcome everyone to the Ligand First Quarter 2024 Earnings Webcast. All lines have been placed on mute to prevent any background noise. After the speakers' remarks, there will be a question and answer session. [Operator Instructions] Thank you. I would now like to turn the call over to Michael Jeong, Investor Relations. Please go ahead.

NASDAQ.LGND price evolution

Want to become a better investor?

Start tracking your investments with Statfolio

Sign up for free
Related News
The past three years for Ligand Pharmaceuticals (NASDAQ:LGND) investors has not...

Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) shareholders should be happy to see the share...

Simply Wall St. · via Yahoo Finance 20 Jun 2024

Editas (EDIT) Q1 Earnings & Revenues Lag Estimates, Stock Down

Editas Medicine, Inc. EDIT incurred a loss of 76 cents per share in the first quarter of 2024, wi...

Zacks via Yahoo Finance 9 May 2024

Halozyme's (HALO) Q1 Earnings Beat, Revenues Lag Estimates

Halozyme Therapeutics, Inc. HALO reported first-quarter 2024 adjusted earnings of 79 cents per sh...

Zacks via Yahoo Finance 8 May 2024

Ligand (LGND) Beats Q1 Earnings, Misses Sales Estimates

Ligand Pharmaceuticals Incorporated LGND reported core adjusted diluted net income per share of $...

Zacks via Yahoo Finance 8 May 2024

Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Q1 2024 Earnings Call Transcript

Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Q1 2024 Earnings Call Transcript May 7, 2024 Li...

Insider Monkey via Yahoo Finance 8 May 2024

Axsome (AXSM) Q1 Loss Widens Y/Y, Revenues Beat Estimates

Axsome Therapeutics, Inc. AXSM reported an adjusted loss of $1.00 per share for the first quarter...

Zacks via Yahoo Finance 8 May 2024

Roche (RHHBY) Alecensa Wins FDA Nod for Label Expansion

Roche RHHBY announced that the FDA has approved a label expansion of its lung cancer drug, Alecen...

Zacks via Yahoo Finance 19 Apr 2024

Vanda (VNDA) Rejects Takeover Interest From Future Pak, Stock Up

Vanda Pharmaceuticals Inc. VNDA announced that its board of directors has unanimously rejected a ...

Zacks via Yahoo Finance 18 Apr 2024

Neumora (NMRA) Down on FDA Clinical Hold on Neurology Drug

Neumora Therapeutics, Inc. NMRA announced that the FDA has placed a clinical hold on the phase I ...

Zacks via Yahoo Finance 16 Apr 2024

Corcept (CORT) Completes Enrollment in Phase II ALS Study

Corcept Therapeutics Incorporated CORT announced that it has completed enrollment in the phase II...

Zacks via Yahoo Finance 16 Apr 2024